Vectura Prevails In US Litigation Over GSK’s Ellipta
Executive Summary
Vectura has won an award of almost $90m after convincing a Delaware jury that GSK’s Ellipta respiratory range infringed one of its US patents. The firm currently has a development deal with Hikma for generic versions.
You may also be interested in...
Vectura Agrees £958m Takeover Following Hikma Advair Launch
Weeks after partner Hikma launched its generic version of GSK’s Advair, Wiltshire-based Vectura has agreed a takeover offer by private equity Carlyle, which aims to build a market leading inhalation specialist CDMO.
Hikma and Vectura ally on Ellipta rivals
Hikma has announced a global development and marketing collaboration deal with Vectura aimed at developing generic versions of GlaxoSmlithKline’s (GSK’s) Ellipta respiratory portfolio. The agreement on rivals to Ellipta – which builds on an existing collaboration between the two firms to develop a generic version of GSK’s Advair Diskus (fluticasone/salmeterol) – will use Vectura’s proprietary ‘open-inhale-close’ dry-powder inhaler device.
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.